Napredna pretraga

Pregled bibliografske jedinice broj: 790243

Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment


Babić Leko, Mirjana; Borovečki, Fran; Dejanović, Nenad; Hof, Patrick R.; Šimić, Goran
Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment // Journal of Alzheimer's Disease, 50 (2016), 3; 765-778 doi:10.3233/JAD-150705 (međunarodna recenzija, članak, znanstveni)


Naslov
Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment

Autori
Babić Leko, Mirjana ; Borovečki, Fran ; Dejanović, Nenad ; Hof, Patrick R. ; Šimić, Goran

Izvornik
Journal of Alzheimer's Disease (1387-2877) 50 (2016), 3; 765-778

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Visinin-like protein 1; dementia; biomarker; mild cognitive impairment; Alzheimer’s disease; cerebrospinal fluid; early diagnosis

Sažetak
Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer’s disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating MCI patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t- tau, Aβ1-42, p-tau181, p-tau199, and p- tau231).VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau.VILIP-1/Aβ1-42 and VILIP-1/p-tau181ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ1-42 and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/ptau181 and VILIP-1/p- tau231ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1081870-1942 - Fosforilacija tau proteina u razvitku i Alzheimerovoj bolesti (Goran Šimić, )
HRZZ-09/16 - Otkrivanje i praćenje bioloških biljega radi rane terapijske intervencije u Alzheimerovoj bolesti (Goran Šimić, )
IP-2014-09-9730

Ustanove
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati